PURE Bioscience, Inc. (PURE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 7 | 4 | 2 | 2 | 2 | 2 | 2 | - |
| Operating profit | $m | -2 | -2 | ||||||
| Net profit | $m | -0 | -2 | -3 | -4 | -3 | -2 | -2 | - |
| EPS reported | $ | -0.02 | -0.02 | ||||||
| Operating cashflow per share | $ | -0.02 | -0.02 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.02 | -0.02 | ||||||
| Free cash flow | $m | -2,015 | -2 | ||||||
| Net debt | $m | -333 | 6 | ||||||
| Book value equity | $m | -5 | -6 | ||||||
| Book value per share | $ | -0.05 | -0.05 | ||||||
| Number of shares | m | 111.86 | 110.83 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.96 | -1.72 | ||||||
| P/S LTM | x | 4.56 | 4.15 | ||||||
| P/FCF LTM | x | -0.00 | -5.64 | ||||||
| EV/EBITDA LTM | x | 154.16 | -1,748.28 | ||||||
| EV/Sales LTM | x | -146.88 | 5.46 | ||||||
| Earnings Yield LTM | % | -23.88% | -28.42% | ||||||
| FCF Yield | % | -20059.2% | -17.72% | ||||||
| Quality | |||||||||
| ROE | % | +46.89% | +38.73% | ||||||
| ROIC | % | -20.45% | -2.91% | ||||||
| Operating margin | % | -1.03% | -79.11% | ||||||
| Gross margin | % | +59.17% | +538.04% | ||||||
| FCF/Sales | % | -91.51% | -73.49% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +12.18% | +23.38% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3,848.36 | -0.27 | ||||||
| Net Debt/EBITDA | x | 158.95 | 29.81 | ||||||
| EBIT/Net interest | x | -7.60 | -0.01 | ||||||
| Net debt/market cap | % | +5.21% | +84.31% | ||||||
| Net debt/Equity | x | 65.18 | -0.94 | ||||||
| Gross debt/equity | x | -0.10 | -1.11 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free